silver has been researched along with Pneumonia, Bacterial in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Gong, C; Yang, J; Zhang, N; Zhao, Y; Zuo, J | 1 |
| Azad, MAK; Baker, MA; Han, M; Hussein, M; Jasim, R; Li, J; Nowell, C; Schneider, EK; Velkov, T; Wang, J | 1 |
| Cui, YX; Ding, J; He, J; Hu, Y; Huo, D; Li, H; Wang, HW; Xia, LY; Zhou, ZY | 1 |
| Berra, L; Kolobow, T; Li Bassi, G | 1 |
4 other study(ies) available for silver and Pneumonia, Bacterial
| Article | Year |
|---|---|
Hyaluronic acid and antimicrobial peptide-modified gold/silver hybrid nanocages to combat bacterial multidrug resistance.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Gold; Human Umbilical Vein Endothelial Cells; Humans; Hyaluronic Acid; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Particle Size; Pneumonia, Bacterial; Pore Forming Cytotoxic Proteins; Silver; Survival Rate | 2020 |
A Fresh Shine onCystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles.
Topics: Administration, Inhalation; Anti-Infective Agents; Bacterial Physiological Phenomena; Cell Survival; Cystic Fibrosis; Diffusion; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Humans; Metal Nanoparticles; Pneumonia, Bacterial; Polymyxin B; Respiratory Therapy; Silver; Treatment Outcome | 2017 |
X-ray CT and pneumonia inhibition properties of gold-silver nanoparticles for targeting MRSA induced pneumonia.
Topics: Animals; Drug Delivery Systems; Gold; Male; Metal Nanoparticles; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Rats; Rats, Wistar; Silver; Tomography, X-Ray Computed | 2014 |
Silver-coated endotracheal tubes: is the bactericidal effect time limited?
Topics: Anti-Bacterial Agents; Biofilms; Coated Materials, Biocompatible; Colony Count, Microbial; Cross Infection; Feasibility Studies; Humans; Intubation, Intratracheal; Pneumonia, Bacterial; Silver | 2007 |